RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MASINI C
Collezione AO Ordine Mauriziano

Items : 10

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). in Future oncology (London, England) / Future Oncol. 2024 May 3:1-19. doi: 10.1080/14796694.2024.2340960.

2024
AO Ordine Mauriziano

Buti S; Galli L; Fornarini G; Llaja Obispo MA; Banna GL; Maffezzoli M; Cremante M; Damassi A; Murianni V; Sbaraglia M; Catalano F; Brunelli M; Signori A; Milella M; Dei Tos AP; Bimbatti D; Cavo A; Vignani F; Merler S; Maruzzo M; Gaggero G; Vellone VG; Galuppini F; Spada M; Masini C; Rescigno P; Rebuzzi SE;

The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO). in Tumori / Tumori. 2024 Jun;110(3):203-208. doi: 10.1177/03008916231222761. Epub 2024 Feb 7.

2024
AO Ordine Mauriziano

Silvestris N; Tralongo P; Tortora G; Bordonaro R; Brandi G; Brunetti O; Carnaghi C; Ciliberto D; Cinieri S; Corallo S; De Vita F; Di Donato S; Ferraù F; Fornaro L; Barucca V; Giommoni E; Lotesoriere C; Luchini C; Masini C; Niger M; Pisconti S; Rapposelli IG; Rimassa L; Rognone C; Rodriquenz MG; Corsini LR; Santin D; Scarpa A; Scartozzi M; et alii...

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Rescigno P; Fornarini G; Buti S; Rebuzzi SE; Vignani F; Cavo A; Signori A; Banna GL; Tudini M; Malgeri A; Nole F; Prati G; Morelli F; Messina M; Di Napoli M; Atzori F; Prati V; Soraru M; Panni S; Mollica V; Pipitone S; Ricotta R; Fratino L; Catalano F; Milella M; Procopio G; Naglieri E; Masini C; Zucal PA; et alii...

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Chiellino S; Galli L; Banna GL; Fornarini G; Rescigno P; Cremante M; Damassi A; Catalano F; Roviello G; Cavo A; Lipari H; Vignani F; Prati G; Spada M; Nolè F; Morelli F; Di Napoli M; Caffo O; Malgeri A; Atzori F; Prati V; Tudini M; Sorarù M; Mollica V; Ricotta R; Baldessari C; Procopio G; Milella M; Fratino L; et alii...

2024
AO Ordine Mauriziano

Fornarini G; Rebuzzi SE; Llaja Obispo MA; Banna GL; Maffezzoli M; Cremante M; Damassi A; Murianni V; Sbaraglia M; Dei Tos AP; Catalano F; Brunelli M; Signori A; Milella M; Bimbatti D; Cavo A; Vignani F; Merler S; Maruzzo M; Vellone VG; Gaggero G; Galuppini F; Masini C; Spada M; Galli L; Buti S; Rescigno P;

Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. in European urology / Eur Urol. 2023 Jan;83(1):82-89. doi: 10.1016/j.eururo.2022.09.025. Epub 2022 Oct 8.

2023
AO Ordine Mauriziano

Santini D; Pierantoni F; Zonno A; Lolli C; Procopio G; Di Napoli M; Ignazzi G; Pignata S; Veccia A; Scandurra G; Gamba T; Ermacora P; Aieta M; Masini C; Hamzaj A; Atzori F; Stellato M; Carella C; Giannatempo P; Bimbatti D; De Giorgi U; Tambaro R; Vignani F; Di Maio M;

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20

2021
AO Ordine Mauriziano
ASL Cuneo 2

Buti S; Porta C; Perrino M; Brunelli M; Iacovelli R; Paolieri F; Chiellino S; Bersanelli M; Casadei C; Cavo A; Roviello G; Pierantoni F; Prati G; Vignani F; Nolè F; Morelli F; Messina M; Pignata S; Messina C; Stellato M; Atzori F; Soto Parra HJ; Cortellini A; Prati V; Sorarù M; Santoni M; Mollica V; Panni S; Fratino L; et alii...

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2019 Feb;17(1):e150-e155. doi: 10.1016/j.clgc.2018.10.001. Epub 2018 Oct 10.

2019
AO Ordine Mauriziano

Masini C; Vitale MG; Maruzzo M; Procopio G; de Giorgi U; Buti S; Rossetti S; Iacovelli R; Atzori F; Cosmai L; Vignani F; Prati G; Scagliarini S; Guida A; Berselli A; Pinto C;

CORE-URO-01 study: Comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure in Annals of Oncology

2017
AO Ordine Mauriziano
ASL Cuneo 2
AOU San Luigi di Orbassano

Masini C; Vitale MG; Maruzzo M; Procopio G; De Giorgi U; Buti S; Rossetti S; Iacovelli R; Guida A; Atzori F; Mucciarini C; Cosmai L; Vignani F; Prati G; Scagliarini S; Berselli A; Pinto C; Baldari S; Annibale V; Lastoria S; Tucci M; Borsatti E; Monari F; Paganelli G; Verri E; Muto P; Panareo S; Mosca A; Storto G; et alii...

CORE-URO-01 study: Comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure in Annals of Oncology

2017
AO Ordine Mauriziano

Masini C; Vitale MG; Maruzzo M; Procopio G; De Giorgi U; Buti S; Rossetti S; Iacovelli R; Guida A; Atzori F; Mucciarini C; Scagliarini S; Vignani F; Prati G; Cosmai L; Berselli A; Pinto C;